Hillstream BioPharma, Inc. (HILS)

$0.81

-0.01 (-0.72%)
Rating:
Recommendation:
-
Symbol HILS
Price $0.81
Beta 0.000
Volume Avg. 0.21M
Market Cap 9.339M
Shares () -
52 Week Range 0.65-4.24
1y Target Est -
DCF Unlevered HILS DCF ->
DCF Levered HILS LDCF ->
ROE -359.55% Strong Sell
ROA -69.35% Strong Sell
Operating Margin -
Debt / Equity 8.25% Neutral
P/E -
P/B 1.04 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest HILS news


Healthcare
Biotechnology
NASDAQ Capital Market

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.